Guangdong Engineering Research Center of Chinese Medicine & Disease Susceptibility, Jinan University, Guangzhou 510632, China.
Institute of Traditional Chinese Medicine and Natural Products, College of Pharmacy, Jinan University, Guangzhou 510632, China.
Int J Mol Sci. 2018 Oct 20;19(10):3266. doi: 10.3390/ijms19103266.
Herpes simplex virus type 1 (HSV-1) is the most common virus, with an estimated infection rate of 60⁻95% among the adult population. Once infected, HSV-1 can remain latent in the host for a lifetime and be reactivated in patients with a compromised immune system. Reactivation of latent HSV-1 can also be achieved by other stimuli. Though acyclovir (ACV) is a classic drug for HSV-1 infection, ACV-resistant strains have been found in immune-compromised patients and drug toxicity has also been commonly reported. Therefore, there is an urge to search for new anti-HSV-1 agents. Natural products with potential anti-HSV-1 activity have the advantages of minimal side effects, reduced toxicity, and they exert their effect by various mechanisms. This paper will not only provide a reference for the safe dose of these agents if they are to be used in humans, referring to the interrelated data obtained from in vitro experiments, but also introduce the main pharmacodynamic mechanisms of traditional Chinese medicine (TCM) against HSV-1. Taken together, TCM functions as a potential source for HSV-1 therapy by direct (blocking viral attachment/absorption/penetration/replication) or indirect (reducing the susceptibility to HSV-1 or regulating autophagy) antiviral activities. The potential of these active components in the development of anti-HSV-1 drugs will also be described.
单纯疱疹病毒 1 型(HSV-1)是最常见的病毒,估计成年人中的感染率为 60⁻95%。一旦感染,HSV-1 可以在宿主体内潜伏终生,并在免疫系统受损的患者中被重新激活。潜伏的 HSV-1 的重新激活也可以通过其他刺激来实现。虽然阿昔洛韦(ACV)是治疗 HSV-1 感染的经典药物,但在免疫功能低下的患者中已经发现了耐 ACV 的菌株,并且也经常报道药物毒性。因此,迫切需要寻找新的抗 HSV-1 药物。具有潜在抗 HSV-1 活性的天然产物具有副作用小、毒性低的优点,并且通过多种机制发挥作用。本文不仅将参考从体外实验获得的相关数据,为这些药物如果在人类中使用提供安全剂量的参考,还将介绍中药(TCM)抗 HSV-1 的主要药效学机制。总的来说,TCM 通过直接(阻断病毒的附着/吸收/渗透/复制)或间接(降低对 HSV-1 的易感性或调节自噬)抗病毒活性,成为 HSV-1 治疗的潜在来源。还将描述这些活性成分在开发抗 HSV-1 药物方面的潜力。